NEW YORK, May 22, 2002 (PRIMEZONE) -- Kodak's trailing 12 months' OPS(TM) (Operational-cashflow Per Share) increases 75% to a five-year record and StockDiagnostics.com has upgraded Eastman Kodak Company (NYSE:EK) to an OPS Rating(TM) of "1." An OPS Rating of "1" is the highest that a company can achieve. OPS Ratings on more than 7,500 companies can be found at: http://www.stockdiagnostics.com
Kodak's OPS Rating increase was justified by its recently filed Cash Flow Statements for its first quarter ended March 31, 2002. Its computed OPS (Operational-cashflow Per Share) for the quarter was a $.17 per share as compared with a ($.17) per share for the quarter ended March 31, 2001. To view Kodak's quarterly OPS Diagnostic chart go to: http://www.stockdiagnostics.com/member/company/20qtrs/91/20291.htm.
Kodak's OPS for its most recent 12 months ended March 31, 2002 increased 75% to $7.44 per share as compared with $4.24 per share for the 12 months ended March 31, 2001. Kodak's OPS for its most recent 12 months was the highest recorded for any 12-month period ending on March 31. To view Kodak's "5 year history-trailing 12 month" OPS Diagnostic chart go to: http://www.stockdiagnostics.com/member/company/5yrs/91/20291.htm
For information on OPS (Operational-cashflow Per Share) go to: http://www.stockdiagnostics.com/member/ops.htm
How are OPS Ratings determined?
OPS Ratings were discovered from StockDiagnostics.com's in-depth research on Operational Cash Flow. These studies revealed that a company's OPS (Operational-cashflow Per Share) logically falls into a mathematical sequence that ranks it into one of eight distinctive risk categories. Ratings are scaled 1 through 8, with number one (1), being the highest rating and number eight (8), the lowest. A "Ratings Suspended" status is given for all companies diagnosed with The EPS Syndrome(TM) during the most recent four quarters.
For more information on OPS Ratings go to: http://www.stockdiagnostics.com/member/ops_rating.htm
For information on The EPS Syndrome go to: http://www.stockdiagnostics.com/member/eps_syndrome.htm
About StockDiagnostics.com
StockDiagnostics.com has designed and built a proprietary data refinery that automates the process of collecting, sorting and organizing large amounts of securities pricing and financial data into comparative financial ratios. These ratios are used to identify Financial Statement and securities pricing variances or anomalies and to monitor changes in the performance of public companies.
For more information on StockDiagnostics.com.go to: http://www.stockdiagnostics.com/member/help.htm#a1
Disclaimer:
The information provided by StockDiagnostics.com does not constitute a recommendation by StockDiagnostics.com to buy, sell, hold any security, or to follow any particular trading or investment strategy. Also, the information provided should not be construed as an offer, or a solicitation of an offer, to buy or sell securities. An Investor's best course of action must be based upon individual circumstances. StockDiagnostics.com shall not be liable for any damages or costs of any type arising out of or in any way connected with your use of our services.